The presentation may provide updates on Phase 3/2 trial timelines and regulatory milestones. Watch for any data readouts or guidance on NDA submission plans for HLP003, which could be a catalyst given the Breakthrough Therapy Designation.
Price Chart
Executive Summary
Helus Pharma announced an investor presentation scheduled for October 21, 2026, to discuss its Phase 3 MDD candidate HLP003 and Phase 2 GAD candidate HLP004. The filing is a routine event announcement with no new financial data or clinical results, but it occurs in the context of recent activist SC 13D filings (Eric So and Paul Glavine) that add pressure for pipeline progress.
Key Facts
- Investor presentation scheduled for October 21, 2026 at 9:00 a.m. EDT.
- Topics include HLP003 (Phase 3 for MDD, Breakthrough Therapy Designation) and HLP004 (Phase 2 for GAD).
- Presentation will include key opinion leaders and Q&A with executive leadership.
- Two SC 13D filings by Eric So and Paul Glavine were filed 29 days prior, indicating activist interest.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- No new clinical data or financial results provided — presentation may be high-level without material updates.
- Activist filings (SC 13D) suggest potential pressure for strategic changes, which could distract from pipeline execution.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001833141-26-000089 |
| Document: heluspharmainc-form6xk10x0.htm | 0001833141-26-000089 |
| Document: 0001833141-26-000089-index-headers.html | 0001833141-26-000089 |
| Document: 0001833141-26-000089-index.html | 0001833141-26-000089 |
| Document: 0001833141-26-000089.txt | 0001833141-26-000089 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $10.66 | awaiting T+20 | — | $10.36 (−2.77%) |
Oct 26, 2026 1d ago | 3 | $10.36 | awaiting T+20 | — | $10.36 (−0.00%) |
Oct 26, 2026 1d ago | 3 | $10.36 | awaiting T+20 | — | $10.36 (−0.00%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | — | $10.36 (−0.00%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | — | $10.36 (−0.00%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | — | $10.36 (−0.00%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | — | $10.36 (−0.00%) |
Oct 21, 2026 6d ago | 6-K | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 15, 2026 12d ago | 6-K | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 15, 2026 12d ago | Press Release | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers